Data Analysis Service (DAS)

Data Analysis Service (DAS) provides reports generated and delivered by a team of NanoString scientific leads and supporting analysts/biostaticians.

Multi-Device-Mock-up-IO-360-Data-Report.png

  • Professional analysis from expert scientists who know NanoString data best
  • Highly consultative
  • Publication-ready figures
  • Fast turn-around time
  • Interactive one-on-one data review

Customizable analysis services are also available.

 

360 Analysis Reports

 

 

Data analysis report for the nCounter® PanCancer IO 360™ Gene Expression Panel

  • Unique 360 view of gene expression for the tumor, microenvironment and immune response
  • Interactive reports prepared by NanoString expert scientists
  • 48 signatures including TIS, 14 signatures measuring immune cell populations and 34 novel signatures measuring important tumor and immune activities
  • Tumor Inflammation Score (TIS) provided for each sample to determine “hot” and “cold” tumors
  • Analysis includes sample signature score in relation to immune response
  • All data undergoes QC and normalization
  • Flexibility to include up to 5 additional user-defined signatures based on IO 360 or Panel Plus genes
  • Standard report currently available for human only

Expedite analysis to insight: 48 signatures provide a multi-faceted view of the tumor immune interplay.

Tumor Immunogenicity Tumor Sensitivity to Immune Attack Inhibitory Immune Mechanisms Stromal Factors Inhibitory Metabolism Anti-Tumor Immune Activity Inhibitory Immune Signaling Immune Cell Population Abundance
Antigen Processing Machinery Apoptosis IDO1 Gene Expression Endothelial Cells Glycolysis Tumor Inflammation Signature (TIS) CTLA4 Gene Expression B Cells NK CD56dim Cells
Antigen Presenting Machinery Expression Loss Tumor Proliferation PD-L1 Gene Expression Stromal Tissue Abundance Hypoxia Cytotoxicity IL10 Gene Expression CD45+ Cells Natural Killer Cell Abundance
Immunoproteasome JAK-STAT Pathway Gene Expression Loss B7-H3 Gene Expression Interferon Gamma Signaling Inflammatory Chemokines CD8 T Cell T Cells Abundance
MAGE Genes Expression TGF-Beta Gene Expression Interferon Signaling Response Myeloid-Derived Inflammatory Signaling Cytotoxic Cells TH1 Cell (TBX21/T-bet) Expression
Loss of Mismatch Repair Gene Expression Lymphoid Compartment Activity PD-1 Gene Expression Dendritic Cells Treg (FOXP3 Expression)
Hypermutation MHC Class II Antigen Presentation PD-L2 Gene Expression Exhausted CD8 Cell
MSI Predictor Myeloid Compartment Activity TIGIT Gene Expression Macrophage
ARG1 Gene Expression Mast Cells
NOS2 Gene Expression Neutrophils

Explore the Interactive IO360 Demo Report today!

IM_MK2255_Gx Panel Images_FINAL.png

Data analysis report for the nCounter® Breast Cancer 360™ Gene Expression Panel

  • Interactive report provides a 360 degree view of gene expression for the breast tumor microenvironment and immune response
  • 48 signatures across 13 categories of breast cancer tumor biology
  • PAM50 intrinsic subtype provided for each sample to determine luminal A, luminal B, HER2-enriched, or basal-like subtypes.
  • Tumor Inflammation Signature (TIS) score provided for each sample to determine “hot” and “cold” tumors
  • Signature scores as a function of response, treatment, and survival where annotations are provided
  • Time series analysis available to determine how signatures are changing through time
Breast Cancer Prognosis Genomic Risk / Risk of Recurrence              
Breast Cancer Subtyping PAM50 Molecular Subtypes Luminal A Correlation Value (PAM50) Luminal B Correlation Value (PAM50) HER2-Enriched Correlation Value (PAM50) Basal-like Correlation Value (PAM50) Claudin-Low Subtype Score Triple Negative Subtype  
Breast Cancer Receptors ESR1 Gene Expression PGR Gene Expression ERBB2 Gene Expression AR Gene Expression        
Breast Cancer Signaling Pathways ER Signaling PTEN Gene Expression CDK4 Expression CDK6 Expression        
Tumor Mutational Response HRD BRCA p53          
Tumor Regulation Proliferation (PAM50) Apoptosis Differentiation FOXA1 Gene Expression Cell Adhesion Mammary Stemness RB1 Gene Expression SOX2 Gene Expression
Tumor Immunogenicity APM (Antigen Processing Machinery)              
Stromal Factors Endothelial Cells Stromal Abundance            
Inhibitory Metabolism Hypoxia              
Inhibitory Immune Mechanisms IDO1 Expression PD-L1 Gene Expression B7-H3 TGF-Beta        
Anti-Tumor Immune Activity Tumor Inflammation Signature (TIS) Interferon Gamma Signaling MHC Class II Antigen Presentation Cytotoxicity        
Inhibitory Immune Signaling Inflammatory Chemokines TIGIT Gene Expression PD-L2 Gene Expression PD-1 Gene Expression        
Immune Cell Abundance Cytoxic Cell CD-8+ T Cell Macrophage Mast Cell Treg      

Explore the Interactive BC360 Demo Report today!

IM_MK2481_BC360-Web-Content.png


General Information

Individual Signature Analysis

The following signature is available on an à la carte basis:

The Tumor Inflammation Signature (TIS) quantifies the magnitude of a peripherally suppressed, adaptive immune response in the tumor microenvironment. It has been trained and validated by Merck to predict response to single agent Pembrolizumab, independent of tumor cell of origin.

The following signature is available on an à la carte basis:

PAM50 intrinsic breast cancer subtypes used in this analysis defines 4 prototypical subtypes Basal, Her2-Enriched, Luminal B and Luminal A. The clinical and prognostic characteristics of these subtypes are extensively studied. If clinical tumor size is provided, the PAM50 report will also include the Risk of Recurrence (ROR) score. If the number of positive nodes is provided, the PAM50 report will also include Risk Category.

The following signature is available on an à la carte basis:

The Lymphoma Subtyping Test is based on the Leukemia and Lymphoma Molecular Profiling Project Lymph2Cx assay and provides cell of origin data for diffuse large B-cell lymphomas. The LST report includes the Linear Predictor Score (LPS) and the DLBCL cell of origin subtype: GCB, ABC, or Unclassified.


IO 360 Participating CROs:

 

 

For Research Use Only. Not for use in diagnostic procedures.